Participating Faculty

Supplements and Featured Publications, Improving Post-PCI Outcomes: Therapeutic Considerations for Managed Care [CME/CPE], Volume 15, Issue 2 Suppl

This supplement to The American Journal of Managed Care provides information on the risk management of patients after percutaneous coronary intervention following an acute coronary event. Novel managed care interventions to improve the quality of care for acute coronary syndromes and manage the financial burden of the disease are discussed.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Participating Faculty

Jason Cross, PharmD, RPh

Assistant Professor of Pharmacy Practice

Department of Pharmacy Practice

Massachusetts College of Pharmacy and Health Sciences

Worcester, Massachusetts

Daniel M. Kolansky, MD

Associate Professor of Medicine

Division of Cardiovascular Medicine

University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania

Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology)

Professor of Clinical Pharmacy

Department of Pharmacy Practice and Pharmacy Administration

University of the Sciences in Philadelphia

Philadelphia College of Pharmacy

Philadelphia, Pennsylvania

Additional content planners:

Nimish Mehta, PhD, MBA,

Greselda Butler


Faculty Disclosures

Daniel M. Kolansky, MD

Speakers' Bureau:

Bristol-Myers Squibb Company

Sanofi Pharmaceuticals Partnership

Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology)

Speakers' Bureau:

Bristol-Myers Squibb Company




Jason Cross, PharmD, RPh,

has no financial relationships to disclose.

Nimish Mehta, PhD, MBA,

Greselda Butler

The planning committee members,and , have no financial relationships to disclose.

All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.

Improving Post-PCI Outcomes: Therapeutic Considerations for Managed Care

A CME/CE-certified supplement to The American Journal of Managed Care based on the Continuing Pharmacy Education symposium held on October 15, 2008, in Kansas City, Missouri

Purpose Statement

The purpose of this activity is to educate managed care clinicians about the optimization of patient outcomes after an acute coronary event through timely and appropriate initiation and management of antiplatelet therapy.

Target Audience

This activity has been designed to meet the educational needs of physicians, pharmacists, nurses, and other clinical and health policy decision makers and stakeholders who treat and manage patients following an acute coronary event and operate in a managed care environment.

Educational Objectives

Upon completion of this activity participants will be able to:

  • Describe the medical and economic burden of acute coronary syndromes
  • Identify discrete coronary vascular risks associated with percutaneous coronary intervention (PCI) using bare-metal or drug-eluting stents
  • Interpret current treatment guidelines and recommendations that support dual antiplatelet therapy following PCI so that patient-centered, individualized care can be provided

Pharmacists will be able to:

  • Identify and implement techniques for improving adherence to dual antiplatelet therapy

Accreditation and Credit Designation Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Independent Medical Education, LLC (IME). The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Program # 797-999-09-007-H04-P.

This activity will address practice gaps in knowledge and competence.

This program is designated for up to 1.5 contact hours (.15 CEU s) of continuing pharmacy education credit. Statements of Credit will be mailed 6 to 8 weeks following activity participation, upon completion and return of the evaluation form to the Annenberg Center for Health Sciences at Eisenhower (#4675), 39000 Bob Hope Drive, Rancho Mirage, CA 92270 or by fax to 760-773-4550. There is no charge for this activity.

This activity was originally released in March 2009 and is eligible for credit through March 31, 2010.

This activity is supported by an independent educational grant from Daiichi Sankyo, Inc and Eli Lilly and Company.

The faculty for this activity have disclosed that there will be discussion about the use of products for non-US Food and Drug Administration-approved indications.

This activity is an enduring material and consists of a journal supplement. Successful completion is achieved by reading the material, reflecting on its implications in your practice, and completing the assessment component. The estimated time to complete this activity is 1.5 hours.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.